1522 related articles for article (PubMed ID: 24990162)
1. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
2. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
4. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
6. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
7. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Patel S
Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
10. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
11. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
Murray M; Hatcher H; Jessop F; Williams D; Carroll N; Bulusu R; Judson I
Pediatr Blood Cancer; 2008 Feb; 50(2):386-8. PubMed ID: 17729245
[TBL] [Abstract][Full Text] [Related]
12. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Le Cesne A; Blay JY; Reichardt P; Joensuu H
Oncologist; 2013; 18(11):1192-9. PubMed ID: 24136010
[TBL] [Abstract][Full Text] [Related]
13. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
15. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
[TBL] [Abstract][Full Text] [Related]
16. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
18. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
[TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Xu J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
[TBL] [Abstract][Full Text] [Related]
20. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]